Oslo, Norway and London, UK, 9. July 2019: Arxx Therapeutics, a Scandinavian biotech, and Cancer Research UK, the world’s leading cancer charity, have entered into a licence agreement.
Under the terms of the agreement, Arxx Therapeutics is granted an exclusive and global licence to intellectual property rights to specific anti-S100A4 antibodies.
Tony Hickson, Cancer Research UK’s chief business officer, said: “This agreement will allow further investigation into S100A4, to better understand regulation of cellular processes and how to tackle cancer at a molecular level. This could benefit patients suffering from hard to treat cancers characterised by aggressive growth and spread, such as pancreatic and triple negative breast cancers, for which there are few therapeutic options available.”
“The expertise and collaborative approach at Cancer Research UK means it is uniquely positioned to help drive cancer innovation through industry partnerships and speed up the development of new treatments for those affected by the disease.”
“As disease upregulated extracellular S100A4 is responsible for eliciting excessive activation of the pro-fibrotic, pro-inflammatory and tumor-promoting microenvironment, neutralization of extracellular S100A4 represents a compelling and novel approach to treat a range of human indications, spanning from autoimmune and fibrotic diseases to metastatic cancers. We are excited to partner with Cancer Research UK, to seek out novel treatments for a range of human diseases where current treatment options are limited and medical need is high,” commented Hamed Brodersen, Chairman of Arxx Therapeutics.
The lead drug candidate, 6B12, is a first-in-class, high-affinity, selective monoclonal antibody against S100A4, which has been validated both in vitro and in vivo in different disease models and consistently shown to effectively neutralise the extracellular effects of S100A4 and produce robust disease inhibiting effects.
This programme originated through research at the Danish Cancer Society and was then assigned to Cancer Research UK to seek out commercial partnership opportunities for its development.